Neoadjuvant Sequential Docetaxel Followed by High‐Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial

To report the results of the DECT trial, a phase II study of locally advanced or operable HER2‐positive breast cancer (BC) treated with taxanes and concurrent anthracyclines and trastuzumab. Eligible patients (stage IIA‐IIIB HER2‐positive BC, 18–75 years, normal organ functions, ECOG ≤1, and left ve...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Cell Physiol
Egile Nagusiak: Pizzuti, Laura, Barba, Maddalena, Giannarelli, Diana, Sergi, Domenico, Botti, Claudio, Marchetti, Paolo, Anzà, Michele, Maugeri‐Saccà, Marcello, Natoli, Clara, Di Filippo, Simona, Catenaro, Teresa, Tomao, Federica, Amodio, Antonella, Carpano, Silvia, Perracchio, Letizia, Mottolese, Marcella, Di Lauro, Luigi, Sanguineti, Giuseppe, Di Benedetto, Anna, Giordano, Antonio, Vici, Patrizia
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Original Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089631/
https://ncbi.nlm.nih.gov/pubmed/27187274
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.25432
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak